TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3093237

Group type: EXPERIMENTAL
Intervention: 900 mg lithium carbonate daily for 3 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (3 nights)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (3 nights during therapy)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Post-treatment (2 registrations after lithium carbonate was discontinued)
Number of subjects: 5
Study: 31725332

Group type: EXPERIMENTAL
Intervention: FVG
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FVG + CD
Number of subjects: 21
Study: 29943430

Group type: EXPERIMENTAL
Intervention: Bundled self‐management intervention (Taking control of your phosphate with the 4Ds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 27871595

Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscopy (KVVL)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscopy (KVVL) and Direct laryngoscopy (DL)
Number of subjects: 88
Study: 24814890

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (three doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intra-articular tranexamic acid
Number of subjects: 80
Study: 23009373

Group type: EXPERIMENTAL
Intervention: Individual training and counselling programme
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 20122351

Group type: EXPERIMENTAL
Intervention: Mint-flavoured, alcohol-based mouthwash
Number of subjects: 15

Group type: COMPARATOR
Intervention: Plain water (placebo)
Number of subjects: 15
Study: 18801404

Group type: EXPERIMENTAL
Intervention: Buprenorphine (highest dose 32 mg/day)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Methadone (highest dose 200 mg/day)
Number of subjects: 218
Study: 15739214

Group type: EXPERIMENTAL
Intervention: Lateral sphincterotomy (LAS)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lateral sphincterotomy (LAS) and tailored sphincterotomy (TS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Oral nifedipine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: All treatment groups (LAS, TS, and nifedipine)
Number of subjects: 132
Study: 14716878

Group type: EXPERIMENTAL
Intervention: 131I-HAb18F(ab')2 injected into the target hepatic artery at doses of 0.5, 0.75, 1.0 mCi/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lugol's Liquid to block the thyroid gland
Number of subjects: 24
Study: 10362732

Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mg. kg-1. h-1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-NAME (75 or 180 micrograms . kg-1. h-1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 21
Study: 8895035

Group type: EXPERIMENTAL
Intervention: Salt substitute (50% NaCl, 40% KCL, 10% Mg2+)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Whole salt intake
Number of subjects: 40
Study: 2034831

Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: FET
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study: 6661351

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31870338

Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 995

Group type: COMPARATOR
Intervention: Mustard seed oil (MO)
Number of subjects: 995
Study: 27411361

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with AV delay optimization
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with reduced LV activation time
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Presence of ventricular fusion
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Shortening AV delay in patients with ventricular fusion
Number of subjects: 87
Study: 26070467

Group type: COMPARATOR
Intervention: Angio-Seal(®)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Exo-Seal(®)
Number of subjects: 319
Study: 24255104

Group type: EXPERIMENTAL
Intervention: Salsalate 3.5 g/day for 48 weeks
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 22971188

Group type: EXPERIMENTAL
Intervention: High UVA-protection sunscreen applied at 2 mg/cm²
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low UVA-protection sunscreen applied at 2 mg/cm²
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High UVA-protection sunscreen applied at 1 mg/cm²
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low UVA-protection sunscreen applied at 1 mg/cm²
Number of subjects: 15
Study: 19200365

Group type: EXPERIMENTAL
Intervention: SCRT (25 Gy in five fractions of 5 Gy) plus TME-surgery within 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: RCT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks later
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups receive adjuvant chemotherapy (12 weeks continuous infusional 5-FU)
Number of subjects: 0
Study: 17095923

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.3 g x kg(‐1) body mass in 1 L of fluid)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 7
Study: 15266180

Group type: EXPERIMENTAL
Intervention: 99mTc‐depreotide (NeoTect)
Number of subjects: 9
Study: 11354392

Group type: EXPERIMENTAL
Intervention: Clarithromycin MR 500 mg once daily
Number of subjects: 244

Group type: COMPARATOR
Intervention: Clarithromycin IR 250 mg twice daily
Number of subjects: 244
Study: 9272404

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7877334

Group type: EXPERIMENTAL
Intervention: Electric acupuncture (EA) at Chen Time (7 a.m. to 9 a.m.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electric acupuncture (EA) at Xu Time (7 p.m. to 9 p.m.)
Number of subjects: 0
Study: 3155334

Group type: EXPERIMENTAL
Intervention: Dentine adhesives and composites used in combination
Number of subjects: 152
Study: 31852207

Group type: COMPARATOR
Intervention: Sevoflurane + high-dose remifentanil (SH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane + low-dose remifentanil (SL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol + high-dose remifentanil (PH)
Number of subjects: 60
Study: 31076468

Group type: EXPERIMENTAL
Intervention: ICH-1 formula (12.3% incidence of haematoma enlargement at 24 hours)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-2 formula (7.5% incidence of haematoma enlargement at 24 hours)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo (7.8% incidence of haematoma enlargement at 24 hours)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-1 formula (1.1% incidence of haematoma enlargement on day 10)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-2 formula (3.1% incidence of haematoma enlargement on day 10)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo (1.1% incidence of haematoma enlargement on day 10)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-1 formula (2.8% mortality rate)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-2 formula (0.9% mortality rate)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo (3.8% mortality rate)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-1 formula (6.0% poor prognosis incidence)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-2 formula (4.8% poor prognosis incidence)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo (7.1% poor prognosis incidence)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-1 formula (12.1% treatment-emergent adverse events)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo (5.8% treatment-emergent adverse events)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ICH-2 formula (2.8% treatment-emergent adverse events)
Number of subjects: 324
Study: 28266765

Group type: EXPERIMENTAL
Intervention: OCV-C02 (0.3 mg/body)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OCV-C02 (1 mg/body)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OCV-C02 (3 mg/body)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OCV-C02 (6 mg/body)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OCV-C02 (0.3 to 6 mg/body)
Number of subjects: 24
Study: 25719544

Group type: EXPERIMENTAL
Intervention: Fisher & Paykel face mask
Number of subjects: 56

Group type: COMPARATOR
Intervention: Laerdal face mask
Number of subjects: 56
Study: 24096971

Group type: EXPERIMENTAL
Intervention: School-based obesity prevention program
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 405
Study: 21518064

Group type: EXPERIMENTAL
Intervention: Abrupt awakening at 03:00h (<3h sleep)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group slept until 07:30h
Number of subjects: 20
Study: 18054354

Group type: EXPERIMENTAL
Intervention: Robotic tubal anastomosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparotomy tubal anastomosis
Number of subjects: 0
Study: 16794386

Group type: EXPERIMENTAL
Intervention: Prophylactic ilioinguinal neurectomy (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ilioinguinal nerve preservation (group B)
Number of subjects: 100
Study: 14678271

Group type: EXPERIMENTAL
Intervention: Nicotinamide (4 g orally, total dose of 8 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11936571

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg on Days 1-7; 400 mg on Days 8-28) + Dextroamphetamine (20 mg on Days 22-28)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Modafinil (200 mg on Days 1-7; 400 mg on Days 8-28)
Number of subjects: 32
Study: 11928147

Group type: EXPERIMENTAL
Intervention: Transmandibular implant (TMI)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IMZ implant
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Brånemark system (BRA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clinical Implant Performance scale (CIP)
Number of subjects: 88
Study: 7774069

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CSA) at doses <5 mg/kg/day
Number of subjects: 29
Study: 2626336

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (50 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 5077919

Group type: EXPERIMENTAL
Intervention: Spontaneous reporting of adverse reactions to drugs
Number of subjects: 82
Study: 31411968

Group type: EXPERIMENTAL
Intervention: Targeted biopsies alone (n=283)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Nontargeted biopsies (n=357)
Number of subjects: 640
Study: 30696178

Group type: EXPERIMENTAL
Intervention: 10-Gbaud PSK Y-00 quantum stream cipher transmission system
Number of subjects: 0
Study: 27712461

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate treatment (n = 218 teeth)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Laser treatment (n = 216 teeth)
Number of subjects: 62
Study: 25791540

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine (10 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intramuscular haloperidol (5 mg) plus lorazepam (2 mg)
Number of subjects: 67
Study: 23335971

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT) - 40 sessions over 2 months, 5 days/week, 90 minutes each, 100% oxygen at 2 ATA
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (cross group) - no treatment for 2 months followed by 40 HBOT sessions
Number of subjects: 74
Study: 21617163

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon plus EPC stent
Number of subjects: 120

Group type: COMPARATOR
Intervention: EPC stent alone
Number of subjects: 120
Study: 19905932

Group type: EXPERIMENTAL
Intervention: Biphasic calcium composite (BCC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Autogenous bone spongiosa (ABS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 45
Study: 16940980

Group type: EXPERIMENTAL
Intervention: CPT-11 (90 mg/m(2) three times weekly) concomitant to hyperfractionated accelerated radiotherapy (HART)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CPT-11 and HART
Number of subjects: 33
Study: 14752416

Group type: EXPERIMENTAL
Intervention: Hemoglobin raffimer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (10% pentastarch)
Number of subjects: 60
Study: 11275541

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 68
Study: 9129484

Group type: EXPERIMENTAL
Intervention: Single dose of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) at 2100
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Divided doses of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) at 2100 and 0200
Number of subjects: 7
Study: 7964948

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dosage of 30 to 38 Gy in 2- to 3.6-Gy fractions
Number of subjects: 1617

Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (PCI)
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 1617
Study: 3581696

Group type: EXPERIMENTAL
Intervention: Cytotoxic drug treatment (T-group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Symptomatic drugs only (NT-group)
Number of subjects: 22
Study: 30852882

Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 90
Study: 29625014

Group type: EXPERIMENTAL
Intervention: In-group waited, out-group did not wait
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control condition (assigned to a group with no information about delay behavior)
Number of subjects: 2
Study: 26652606

Group type: EXPERIMENTAL
Intervention: Live More intervention (n=24)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control receiving only country specific Ministry of Health literature (n=24)
Number of subjects: 288
Study: 23238223

Group type: EXPERIMENTAL
Intervention: modified constraint induced movement therapy (mCIMT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 31
Study: 21409353

Group type: EXPERIMENTAL
Intervention: Honan's balloon applied during peribulbar anesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: No ocular compression (control group)
Number of subjects: 120
Study: 18672299

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16611388

Group type: EXPERIMENTAL
Intervention: 20 mg policosanol daily for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 14508426

Group type: EXPERIMENTAL
Intervention: Health professional visit
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intervention group 1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intervention group 2
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intervention group 3
Number of subjects: 90
Study: 10753259

Group type: EXPERIMENTAL
Intervention: Vitamin A therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8833493

Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiogram (SA-ECG) analysis using fast-Fourier transformation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Filter processing of low frequency components
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Area ratios of 40-100 Hz/0-40 Hz
Number of subjects: 23
Study: 1534467

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controlled ventilation
Number of subjects: 40
Study: 6536519

Group type: EXPERIMENTAL
Intervention: Althesin (as alphaxalone) in young group
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Methohexitone in young group
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Althesin (as alphaxalone) in old group
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Methohexitone in old group
Number of subjects: 210
Study: 30393060

Group type: EXPERIMENTAL
Intervention: Self-screening by pregnant women
Number of subjects: 428

Group type: COMPARATOR
Intervention: Screening by health care workers
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Self-screening and screening by health care workers
Number of subjects: 428
Study: 29241838

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 2.2g/day
Number of subjects: 71

Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 71
Study: 27101581

Group type: EXPERIMENTAL
Intervention: IV Methotrexate (MTX), 0.4 mg/kg daily for 5 days every 14 days (25 mg maximum daily dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: IV Actinomycin-D (Act-D), 1.25 mg/m (2 mg maximum dose) every 14 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: IV Methotrexate (MTX)
Number of subjects: 62

Group type: COMPARATOR
Intervention: IV Actinomycin-D (Act-D)
Number of subjects: 62
Study: 24747467

Group type: EXPERIMENTAL
Intervention: Video game (Ace's Adventure)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Didactic session
Number of subjects: 348
Study: 23302428

Group type: EXPERIMENTAL
Intervention: SRP with AMX + MTZ after supragingival scaling
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SRP with AMX + MTZ after SRP
Number of subjects: 45

Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AMX + MTZ after supragingival scaling
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AMX + MTZ after SRP
Number of subjects: 45
Study: 20457173

Group type: EXPERIMENTAL
Intervention: GMP diet (gelatin-milk protein)
Number of subjects: 65

Group type: COMPARATOR
Intervention: SMP diet (sustained milk protein)
Number of subjects: 65

Group type: COMPARATOR
Intervention: SSMP diet (supra-sustained milk protein)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GMP diet
Number of subjects: 65
Study: 17873026

Group type: EXPERIMENTAL
Intervention: 8 h of continuous poikilocapnic hypoxia
Number of subjects: 12
Study: 15676045

Group type: EXPERIMENTAL
Intervention: Treatment A (1 mg Bupi and 0.1 mg HA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment B (0.5 mg Bupi and 0.1 mg HA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment C (1 mg Bupi and 0 mg HA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (D)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment C
Number of subjects: 16
Study: 12324672

Group type: EXPERIMENTAL
Intervention: BEC‐HFA 500 micro g/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BEC‐HFA 1000 micro g/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FLU‐HFA 500 micro g/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FLU‐HFA 1000 micro g/day
Number of subjects: 20
Study: 11776508

Group type: EXPERIMENTAL
Intervention: Multiple doses of GnRH antagonist (Cetrotide)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Single dose of GnRH antagonist (Cetrotide)
Number of subjects: 25
Study: 9438891

Group type: EXPERIMENTAL
Intervention: i.v. ondansetron 0.05 mg/kg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: i.v. ondansetron 0.1 mg/kg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: i.v. ondansetron 0.15 mg/kg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.05 mg/kg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.1 mg/kg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.15 mg/kg
Number of subjects: 320

Group type: COMPARATOR
Intervention: i.v. saline (placebo)
Number of subjects: 320
Study: 8339493

Group type: EXPERIMENTAL
Intervention: Unilateral external skeletal fixation with micromovement module
Number of subjects: 45

Group type: COMPARATOR
Intervention: Unilateral external skeletal fixation without micromovement module
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weight bearing during treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Biofeedback mechanism
Number of subjects: 45
Study: 3530094

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: almitrine‐raubasine
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: nicergoline
Number of subjects: 259
Study: 29956424

Group type: EXPERIMENTAL
Intervention: Active tDCS applied to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 27601379

Group type: EXPERIMENTAL
Intervention: Trevo
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Solitaire
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Other retrievable stents or mechanical devices
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 500
Study: 25613830

Group type: EXPERIMENTAL
Intervention: Emergency department-based nursing intervention (one nurse patient encounter before discharge and two phone calls in the 10 days after discharge)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Emergency department-based nursing intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 203
Study: 23672055

Group type: EXPERIMENTAL
Intervention: Zaoren Anshen capsules (five capsules)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Alprazolam (0.8 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Zaoren Anshen capsules
Number of subjects: 120
Study: 21362526

Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 22
Study: 18618870

Group type: EXPERIMENTAL
Intervention: Warmed and humidified insufflation (WHI)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard cold and dry carbon dioxide (Control)
Number of subjects: 7